Journals / Turkish Journal of Medical Sciences / 2018 / Cilt: 48 - Sayı: 3

Effect of phosphodiesterase-5 inhibition on joint and muscle damage in rats with adjuvant arthritis

Pages
635–643
Publication Date
2022-11-04
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Serum TOS showed significant reductions by tadalafil.Conclusion: The long-acting PDE5 inhibitor tadalafil provides partial protection in a rat model of CFA-induced arthritis possibly viasuppression of oxidant generation.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: This study was designed to examine the effect of tadalafil, a phosphodiesterase (PDE)5 inhibitor, on the severity ofjoint and muscle damage in rats with adjuvant-induced arthritis (AA).Materials and methods: AA was induced by intradermal inoculation into right hind paw of male Sprague Dawley rats (300–450g) with complete Freund’s adjuvant (CFA; 0.1 mL).
📊
Key Findings & Data:AA rats were treated with either tadalafil (10 mg/kg; per oral) alone or alongwith the soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ; 10 mg/kg; intraperitoneally).
💡
Conclusion & Impact:Serum TOS showed significant reductions by tadalafil.Conclusion: The long-acting PDE5 inhibitor tadalafil provides partial protection in a rat model of CFA-induced arthritis possibly viasuppression of oxidant generation.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aim: This study was designed to examine the effect of tadalafil, a phosphodiesterase (PDE)5 inhibitor, on the severity ofjoint and muscle damage in rats with adjuvant-induced arthritis (AA).Materials and methods: AA was induced by intradermal inoculation into right hind paw of male Sprague Dawley rats (300–450g) with complete Freund’s adjuvant (CFA; 0.1 mL). AA rats were treated with either tadalafil (10 mg/kg; per oral) alone or alongwith the soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ; 10 mg/kg; intraperitoneally). Afterdecapitation on day 16, trunk blood was collected for total oxidant status (TOS) and total antioxidant capacity (TAC) assays. The leftmetatarsophalangeal joint and gastrocnemius muscle were excised for microscopic examination. Muscle samples were also evaluated interms of malondialdehyde (MDA), glutathione, and chemiluminescence (CL) levels.Results: In tadalafil-treated AA rats, metatarsophalangeal joints revealed regular morphology of the cartilage with slight destructionand less inflammatory cell infiltration and vascularization in comparison to the controls (microscopic score: 1.17 ± 0.31 vs. 4.17 ± 0.79;P < 0.01). AA rats presented increased gastrocnemius muscle MDA, glutathione, and CL levels compared to the controls (P < 0.01, forMDA; P < 0.05, for glutathione; P < 0.05 for CL). Tadalafil attenuated the increase in CL levels (P < 0.01, for luminol and P < 0.001, forlucigenin). Serum TOS showed significant reductions by tadalafil.Conclusion: The long-acting PDE5 inhibitor tadalafil provides partial protection in a rat model of CFA-induced arthritis possibly viasuppression of oxidant generation.

🔖

Cite This Article

ERCAN, F., BAHADIR, F. E., ALİCAN, Y. İ., KÖROĞLU, M. K., YÜKSEL, M. (2022). Effect of phosphodiesterase-5 inhibition on joint and muscle damage in rats with adjuvant arthritis. Turkish Journal of Medical Sciences, Cilt: 48 - Sayı: 3, 635–643. https://ajindex.com/articles/610362

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Annunziato F, Cosmi L, Liotta F, Maggi E, Romagnani S. Type 17T helper cells-origins, features and possible roles in rheumatic disease. Nat Rev Rheumatol 2009; 5; 325-331.
  2. Mohr W, Wild A, Wolf HP. Role of polymorphs in inflammatory cartilage destruction in adjuvant arthritis of rats. Ann Rheum Dis 1981; 40: 171-176.
  3. Mohr W, Westerhellweg H, Wessinghage D. Polymorphonuclear granulocytes in rheumatic tissue destruction. III. An electron microscopic study of PMNs at the pannus-cartilage junction in rheumatoid arthritis. Ann Rheum Dis 1981; 40: 396-399.
  4. Edwards SW, Hallett MB. Seeing the wood for the trees: the forgotten role of neutrophils in rheumatoid arthritis. Immunol Today 1997; 18: 320-324.
  5. Summers GD, Deighton CM, Rennie MJ Booth AH. Rheumatoid cachexia: a clinical perspective. Rheumatology (Oxford) 2008; 47: 1124-1131.
  6. Castillero E, Martín AI, López-Menduiña M, Granado M, Villanúa MA, López-Calderón A. IGF-I system, atrogenes and myogenic regulatory factors in arthritis induced muscle wasting. Mol Cell Endocrinol 2009; 309: 8-16.
  7. Francis SH, Blount MA, Corbin JD. Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol Rev 2011; 91: 651-690. Zusman RM. Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. Am J Cardiol 1999; 83: 1C-2C. Wallis RM, Corbin JD, Francis SH, Ellis P. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and contractile responses of rabecuae carnie and aortic rings in vitro. Am J Cardiol 1999; 83: 3C-12C. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, Osterloh IH, Gingell C. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996; 8: 47-52. Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-2157. Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth A et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894-2903.
  8. Roustit M, Hellmann M, Cracowski C, Blaise S, Cracowski JL. Sildenafil increases digital skin blood flow during all phases of local cooling in primary Raynaud’s phenomenon. Clin Pharmacol Ther 2012; 91: 813